Industry News
At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated at RDEs Promising combination potential, including no DLTs, encouraging safety data, and clearance of first dose escalation combination cohort of ERAS-0015 (16…
Meet with Christopher Kata, Director of Sales & Marketing and Nick Travers May 3rd – 6th at the SCDM EMEA meeting being held in Copenhagen, Denmark! If you’re attending be sure to to reach out to Christopher and Chris to schedule a one on meeting or just drop by booth at your convenience! We’re looking…
First-in-human study underway evaluating anti-CD36 monoclonal antibody designed to restore metabolic fitness in exhausted T cells, reduce immunosuppressive cells, and enhance antitumor immunity Excerpt from the Press Release: DOVER, Del. & EPALINGES, Switzerland–(BUSINESS WIRE)–Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced the first patient…
The data, generated from a study designed to optimize ongoing test refinement, will be presented at the AACR Annual Meeting in April Excerpt from the Press Release: BRISBANE, Calif., March 18, 2026 /PRNewswire/ — Freenome, an early cancer detection company developing blood-based screening tests, today announced initial development data for its investigational lung cancer screening…
Join Christopher Kata, Director of Sales & Marketing, and Nick Travers, Business Development Director, at ACDM 2026 in Berlin Germany, from March 15-17! If you plan to attend, we invite you to connect with Christopher and Nick to schedule a one‑on‑one meeting, or feel free to visit our booth at your convenience. We look forward…
Excerpt from the Press Release: PRINCETON, N.J., Feb. 20, 2026 /PRNewswire/ — Guerbet, a global specialist in contrast media and solutions for medical imaging, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved a labeling update for Elucirem™ (gadopiclenol) injection. The new indication includes approval for pediatric patients aged 0-2 years…
Join Christopher Kata, Director of Sales & Marketing, and Nick Travers, Business Development Director, at the SCOPE Summit in Orlando, Florida, from February 2-5, 2025. If you plan to attend, we invite you to connect with Christopher and Nick to schedule a one‑on‑one meeting, or feel free to visit our booth at your convenience. We…
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the COG CRO Summit in Raleigh, North Carolina. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with Chris Hamelin…
Excerpt from the Press Release: HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic…
– The collaboration will leverage General Proximity’s OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets. – Induced proximity medicines, powered by the OmniTAC™ platform, enable precise modulation of disease-driving and traditionally undruggable proteins. – General Proximity will identify novel effector-target pairs that can be exploited through induced proximity medicines.…